Want to see JP:7733 full AI Analyst Report?
7733 Stock Chart & Stats
¥2133.00
-¥2.50(-0.14%)
At close: 4:00 PM EDT
¥2133.00
-¥2.50(-0.14%)
Day’s Range― - ―
52-Week Range¥1,302.50 - ¥2,210.50
Previous CloseN/A
Volume1.65M
Average Volume (3M)4.03M
Market Cap
¥1.90T
Enterprise Value¥2.00T
Total Cash (Recent Filing)¥152.19B
Total Debt (Recent Filing)¥318.89B
Price to Earnings (P/E)23.8
Beta0.74
Next Earnings
Nov 10, 2026EPS Estimate
22.25Next Dividend Ex-DateN/A
Dividend Yield3.53%
Share Statistics
EPS (TTM)71.16
Shares Outstanding1,114,485,700
10 Day Avg. Volume5,321,490
30 Day Avg. Volume4,034,336
Financial Highlights & Ratios
PEG Ratio-0.60
Price to Book (P/B)2.04
Price to Sales (P/S)1.64
P/FCF Ratio91.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,413.33Price Target Upside13.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)96.88
Revenue Forecast (FY)¥1.08T
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginRevenue growth and a ~64.7% gross margin indicate Olympus is expanding while retaining substantial value from its medical-device offerings. This combination can support reinvestment in product development, clinical support and installed-base services, helping preserve competitiveness over the next several quarters.
Improved Free Cash FlowTTM free cash flow reached ~¥71.4B, up sharply from ~¥18.2B in FY2026. Stronger cash generation improves Olympus's ability to fund innovation, service its installed base and return capital without relying as heavily on external financing, provided the improvement persists.
Manageable LeverageDebt-to-equity of ~0.43 alongside ~¥747.9B of equity indicates a manageable capital structure. This balance-sheet capacity gives Olympus resilience to fund medical-device development and absorb operating variability, while leaving more flexibility than a highly leveraged profile.
Bears Say
Declining ProfitabilityNet margin fell from ~11.8% in FY2025 to ~6.7% in FY2026 and ~7.5% TTM, despite revenue growth. The decline signals weaker earnings conversion and makes future profitability more dependent on restoring efficiency rather than simply expanding sales.
Rising DebtTTM total debt rose to ~¥318.9B from ~¥239.6B in FY2026. Although leverage remains moderate, the increase can raise financing obligations and reduce flexibility for product investment or shareholder returns if operating performance weakens.
Uneven Cash ConversionTTM free cash flow equals only ~55% of net income, while operating cash flow relative to revenue is modest at ~0.28; FY2024 also had negative free cash flow. This uneven conversion makes reported earnings less dependable as a source of internally funded growth.
Olympus News
7733 FAQ
What was Olympus Corp.’s price range in the past 12 months?
Olympus Corp. lowest stock price was ¥1302.50 and its highest was ¥2210.50 in the past 12 months.
What is Olympus Corp.’s market cap?
Olympus Corp.’s market cap is ¥1.90T.
When is Olympus Corp.’s upcoming earnings report date?
Olympus Corp.’s upcoming earnings report date is Nov 10, 2026 which is in 19 days.
How were Olympus Corp.’s earnings last quarter?
Olympus Corp. released its earnings results on Aug 07, 2026. The company reported ¥17.76 earnings per share for the quarter, beating the consensus estimate of ¥8.64 by ¥9.12.
Is Olympus Corp. overvalued?
According to Wall Street analysts Olympus Corp.’s price is currently Undervalued.
Does Olympus Corp. pay dividends?
Olympus Corp. pays a Semiannually dividend of ¥30 which represents an annual dividend yield of 3.53%. See more information on Olympus Corp. dividends here
What is Olympus Corp.’s EPS estimate?
Olympus Corp.’s EPS estimate is 22.25.
How many shares outstanding does Olympus Corp. have?
Olympus Corp. has 1,114,485,700 shares outstanding.
What happened to Olympus Corp.’s price movement after its last earnings report?
Olympus Corp. reported an EPS of ¥17.76 in its last earnings report, beating expectations of ¥8.64. Following the earnings report the stock price went up 1.816%.
Which hedge fund is a major shareholder of Olympus Corp.?
Currently, no hedge funds are holding shares in JP:7733
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Olympus Corp.
Olympus Corporation, a global enterprise headquartered in Tokyo, Japan, manufactures and distributes high-precision machinery and instrumentation worldwide. The company, originally established in 1919 as Olympus Optical Co., Ltd., adopted its current name in October 2003. Its extensive operations are structured into four primary divisions: Endoscopic Solutions, Therapeutic Solutions, Scientific Solutions, and a segment designated as "Others." The Endoscopic Solutions division specializes in developing and providing gastrointestinal and surgical endoscopes, comprehensive endoscopy systems, and associated repair services. The Therapeutic Solutions segment focuses on products for urology, gynecology, and ear, nose, and throat (ENT) procedures, alongside endo-therapy devices, energy-based surgical tools, and disposable surgical instruments. Within Scientific Solutions, Olympus supplies biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing (NDT) equipment, and X-ray fluorescence (XRF) analyzers. The "Others" segment encompasses biomedical materials and orthopedic equipment. Beyond these core areas, the company also offers a broader array of medical devices, including surgical microscopes, endoscope reprocessing units, electrosurgical tools, and respiratory-endotherapy devices, complemented by system integration and ongoing maintenance services.
7733 Company Deck
7733 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented a mix of significant near-term challenges—most notably product ship holds, FDA observations, one-off costs that reduced gross margin and a 2% revenue guidance downgrade—balanced against clear remediation plans, leadership actions, a majority of held products already released (70%), an asserted China recovery (≈5–6%), maintained midterm targets and a commitment to >100 bps margin expansion beginning FY2027. Near-term financial impact is material, but management articulated specific corrective actions and kept long-term targets unchanged.View all JP:7733 earnings summaries7733 Stock 12 Month Forecast
Average Price Target
¥2,413.33
▲(13.14% Upside)